Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Industrifonden in connection with its investment in Agteria Biotech
Mandate

Vinge advises Industrifonden in connection with its investment in Agteria Biotech

February 13, 2025 M&A Employment and Benefits Disputes

Vinge has advised Industrifonden in connection with their participation as lead investor, together with AgriZeroNZ, in the seed financing round in Agteria Biotech AB.

Agteria Biotech AB is a Swedish start-up dedicated to reducing 1% of the global greenhouse gas emissions through its patent-pending molecule that significantly reduces methane emissions from cattle. The new funding will enable the company to advance towards regulatory approval for its methane-reducing molecule, focusing on safety studies for animals, consumers, and the environment.

The Vinge team consisted primarily of JJohan Larsson, Maria Dahlin Kolvik, Ian Linde (M&A), Åsa Hellstadius, Rebecka Målquist (IP), Simon Söderholm and Agnes Pigg (Employment).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026